Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VXM01 + avelumab
- Development stage
- Unknown
- Lead developer
- Vaximm
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral, Intravenous
01
Overview
VXM01 + avelumab is a combination therapy being investigated for recurrent glioblastoma. VXM01 is an investigational oral anti-VEGFR-2 vaccine designed to activate T-cells to attack tumor vasculature and cancer cells directly. It's based on a live attenuated, orally available bacterial vaccine strain modified to carry vascular endothelial growth factor receptor-2 (VEGFR2) as the target gene. Avelumab (Bavencio) is a PD-L1 inhibitor that blocks signals cancer cells sometimes use to hide from the immune system. The combination aims to enhance immune response against glioblastoma through complementary mechanisms.
- Brand names
- VXM01 + Bavencio
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on VXM01 + avelumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VXM01 + avelumab.